文献速递骨质疏松与代谢性骨病

四烯甲萘醌治疗骨质疏松的疗效与安全性:随机对照试验的系统评价与荟萃分析

The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Osteoporos Int · 2019-02-07

该系统评价与荟萃分析纳入18项随机对照试验共8882例患者,评估四烯甲萘醌治疗骨质疏松的疗效与安全性。与安慰剂相比,四烯甲萘醌可降低ucOC/OC比值并改善腰椎骨密度,但椎体骨折风险降低未达统计学显著,且不良事件发生率显著增加。

要点

  • 四烯甲萘醌较安慰剂改善腰椎骨密度(MD=0.05 g/cm²,95%CI 0.01至0.09)并降低ucOC/OC(MD=-21.78%,95%CI -33.68至-9.87%)。
  • 四烯甲萘醌较安慰剂降低椎体骨折风险未达统计学显著(RR=0.87,95%CI 0.64至1.20)。
  • 四烯甲萘醌较安慰剂增加不良事件(RR=1.47,95%CI 1.07至2.02)和药物不良反应(RR=1.29,95%CI 1.07至1.56)发生率,严重不良事件无显著差异。

核心结论

  • 四烯甲萘醌显著降低骨钙素未羧化比例(ucOC/OC),并可能改善骨质疏松患者腰椎骨密度,但其在骨折风险控制方面的获益尚不确定。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Cochrane Library、Embase、ClinicalTrials.gov及三个中文文献数据库(CNKI、CBM、万方),纳入2017年10月5日前发表的比较四烯甲萘醌与其他抗骨质疏松药物或安慰剂的随机对照试验,共纳入18项RCT、8882例患者。

主要发现

  • 与安慰剂相比,四烯甲萘醌改善腰椎骨密度(5项研究,N=658,MD=0.05 g/cm²,95%CI 0.01至0.09 g/cm²)。
  • 与安慰剂相比,四烯甲萘醌降低ucOC/OC(2项研究,N=75,MD=-21.78%,95%CI -33.68%至-9.87%)。
  • 与安慰剂相比,四烯甲萘醌降低椎体骨折风险未达统计学显著(5项研究,N=5508,RR=0.87,95%CI 0.64至1.20)。
  • 与其他抗骨质疏松药物比较的证据有限,四烯甲萘醌对骨密度或骨折风险的影响无显著差异。
  • 与安慰剂相比,四烯甲萘醌显著增加不良事件发生率(2项研究,N=1949,RR=1.47,95%CI 1.07至2.02)和药物不良反应发生率(4项研究,N=6102,RR=1.29,95%CI 1.07至1.56);严重不良事件发生率无显著差异。

关键数值与推荐

  • 四烯甲萘醌改善腰椎骨密度的MD=0.05 g/cm²(95%CI 0.01至0.09 g/cm²,5项研究,N=658)。
  • 四烯甲萘醌降低ucOC/OC的MD=-21.78%(95%CI -33.68%至-9.87%,2项研究,N=75)。
  • 四烯甲萘醌降低椎体骨折风险的RR=0.87(95%CI 0.64至1.20,5项研究,N=5508),未达统计学显著。
  • 四烯甲萘醌增加不良事件的RR=1.47(95%CI 1.07至2.02,2项研究,N=1949)。
  • 四烯甲萘醌增加药物不良反应的RR=1.29(95%CI 1.07至1.56,4项研究,N=6102)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 四烯甲萘醌在骨折风险控制方面的获益尚不确定。
  • 与其他抗骨质疏松药物比较的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In our systematic review and meta-analysis, we comprehensively evaluated menatetrenone in the management of osteoporosis. We found that menatetrenone decreased the ratio of undercarboxylated osteocalcin to osteocalcin (ucOC/OC) and improved lumbar BMD compared with placebo based on the 18 studies assessed. However, its benefit in fracture risk control was uncertain. INTRODUCTION: We performed a systematic review and meta-analysis of the efficacy and safety of menatetrenone in managing osteoporosis. METHODS: PubMed, Cochrane Library, Embase, ClinicalTrials.gov , and three Chinese literature databases (CNKI, CBM, Wanfang) were searched for relevant randomized controlled trials (RCTs) published before October 5, 2017, comparing menatetrenone with other anti-osteoporotic drugs or placebo in treating osteoporosis. The pooled risk ratio (RR) or mean difference (MD) and 95% confidence interval (CI) were calculated using fixed-effects or random-effects meta-analysis. RESULTS: Eighteen RCTs (8882 patients) were included. Pooled analyses showed that menatetrenone was more effective than placebo in improving lumbar bone mineral density (BMD) (five studies, N = 658, MD = 0.05 g/cm2, 95% CI 0.01 to 0.09 g/cm2) and decreasing ucOC/OC (two studies, N = 75, MD = - 21.78%, 95% CI - 33.68 to - 9.87%). Compared with placebo, menatetrenone was associated with a nonsignificantly decreased risk of vertebral fracture (five studies, N = 5508, RR = 0.87, 95% CI 0.64 to 1.20). Evidence on other anti-osteoporotic drugs as comparators was limited and revealed no significantly different effects of menatetrenone on BMD or fracture risks. Furthermore, compared with placebo, menatetrenone significantly increased the incidence of adverse events (AEs) (two studies, N = 1949, RR = 1.47, 95% CI 1.07 to 2.02) and adverse drug reactions (four studies, N = 6102, RR = 1.29, 95% CI 1.07 to 1.56). However, no significant difference in the incidence of serious AEs was found between menatetrenone and placebo. CONCLUSIONS: Menatetrenone significantly decreases ucOC and might improve lumbar BMD in osteoporotic patients. However, its benefit in fracture risk control is uncertain.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Su S, He N, Men P, et al. The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2019. PMID: 30734066. doi:10.1007/s00198-019-04853-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。